Author: Dubar Faustine Khalife Jamal Brocard Jacques Dive Daniel Biot Christophe
Publisher: MDPI
E-ISSN: 1420-3049|13|11|2900-2907
ISSN: 1420-3049
Source: Molecules, Vol.13, Iss.11, 2008-11, pp. : 2900-2907
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Ferroquine (FQ or SR97193) is a novel antimalarial drug candidate, currently in development at Sanofi-Aventis. In contrast to conventional drugs, FQ is the first organometallic drug: a ferrocenyl group covalently flanked by a 4-aminoquinoline and a basic alkylamine. FQ is able to overcome the CQ resistance problem, an important limit to the control of
Related content
Expanding the Antimalarial Drug Arsenal—Now, But How?
By Grimberg Brian T. Mehlotra Rajeev K.
Pharmaceuticals, Vol. 4, Iss. 5, 2011-04 ,pp. :
Amazonian Plant Natural Products: Perspectives for Discovery of New Antimalarial Drug Leads
By Pohlit Adrian Martin Lima Renata Braga Souza Frausin Gina Silva Luiz Francisco Rocha e Lopes Stefanie Costa Pinto Moraes Carolina Borsoi Cravo Pedro Lacerda Marcus Vinícius Guimarães Siqueira André Machado Freitas-Junior Lucio H. Costa Fabio Trindade Maranhão
Molecules, Vol. 18, Iss. 8, 2013-08 ,pp. :
Mechanism of Action and Applications of Interleukin 24 in Immunotherapy
By Persaud Leah De Jesus Dayenny Brannigan Oliver Richiez-Paredes Maria Huaman Jeannette Alvarado Giselle Riker Linda Mendez Gissete Dejoie Jordan Sauane Moira
International Journal of Molecular Sciences, Vol. 17, Iss. 6, 2016-06 ,pp. :